Acrivon Therapeutics, Inc.ACRV

Acrivon Therapeutics, a clinical-stage biotech hunting for precision oncology therapies, told regulators on 13 May 2026 that its first-quarter 2026 loss widened to $19 million and diluted EPS came in at -$0.49 on 38.7 million diluted shares. The company booked $107.8 million in assets at 31 March 2026, but only $34.1 million sat in cash with another $63.7 million parked in short-term investments; operating cash burn ran to -$20.5 million in the same period. In plain English, the business is spending faster than it earns, and the balance sheet is underwriting the gap rather than a product.

What Acrivon actually does is design and develop targeted anti-cancer drugs using its proprietary Generative Phosphoproteomics AP3 platform, which it describes as taking proteomics “one step further.” Its lead asset, ACR-368 (in-licensed from Lilly), is a CHK1/CHK2 inhibitor branded as “clinically-advanced,” while ACR-2316, a WEE1/PKMYT1 inhibitor, is highlighted in a 2025 AACR-NCI-EORTC abstract as “novel” and “designed for optimal pro-apoptotic pathway effects.” The company’s clinical pages list active US trials recruiting patients, but none of the materials supplied show revenue, approvals, or commercial supply agreements. The platform and pipeline are the story; the income statement is the reality.

The 10-Q for the quarter ending 31 March 2026 shows cash used in operating activities of -$20.5 million, net loss attributable to parent of -$19.0 million, and operating loss of -$19.9 million. Short-term investments stood at $63.7 million, cash and equivalents at $34.1 million, and total assets at $107.8 million against liabilities of $12.3 million, leaving shareholders’ equity at $95.5 million. Research and development expense was $15.2 million in the quarter, while capital expenditure was a rounding error at $14,000. Diluted weighted average shares were 38.7 million, producing a headline EPS of -$0.49. The company also operates a 401(k) plan for employees, which it adopted in 2019.

The SEC filings do not provide revenue, gross margin, or operating margin; the income statement is a single-column loss report with no segment breakdowns. The company’s marketing rails tout “best-in-class targeted therapies,” “rational drug design,” and “predictive clinical development,” but the only revenue-linked disclosure is a 10% royalty ceiling on future net sales tied to the Cowen ATM programme that was activated in April 2026. The platform narrative is rich; the filing narrative is thin.

For context on the clinical pipeline, Acrivon lists active US trials recruiting patients and points to a 2025 conference abstract describing ACR-2316 as a differentiated WEE1/PKMYT1 inhibitor designed by the AP3 platform; the abstract’s claims are not independently verified in the filings. The company’s science page repeats the same marketing language (“best-in-class,” “improve the lives of patients”) without quantitative outcomes or timelines for readouts. Until a trial readout, partnering deal, or regulatory milestone appears in an SEC filing, the pipeline remains a promise rather than a product.

Acrivon’s cash runway is underwritten by $34.1 million in cash, $63.7 million in short-term investments, and the potential to raise further capital via its ATM programme with Cowen, but the filings do not disclose the discount or fee terms or the maximum aggregate offering amount. If the company were to monetise its short-term investments at par, it could extend runway; if it issues new shares at a discount, dilution accelerates. The next milestone that would materially change the file is any disclosure of revenue, a clinical readout, or a binding commercial supply or licensing agreement in an SEC filing.

The platform story is compelling on the company’s website and in conference abstracts, but the income statement tells the sharper story: the business is still pre-commercial, pre-revenue, and pre-profitable. The AP3 platform and pipeline remain unproven at scale, and the balance sheet is the only evidence investors can bank on today. Until the company files a quarter with revenue, a profit, or a definitive partnership, the tension sits between the aspirational prose and the unaudited loss column.